Hope for myotonic dystrophy: new drug shows promise in easing muscle stiffness Long-Term
NCT ID NCT06549400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the long-term safety and effectiveness of a drug called mexiletine PR for people with myotonic dystrophy types 1 and 2. The drug is taken once daily as a liquid to help reduce muscle stiffness (myotonia). The study includes 176 adults and teens who have already completed a previous trial. Researchers will measure how quickly hand muscles relax after a strong squeeze and track any side effects over 26 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mexiletine PR (prolonged-release granules for oral suspension)
- What this could lead to
- If successful, this could confirm a safe, long-term treatment option to reduce muscle stiffness and improve daily function for people with myotonic dystrophy.
- What could go wrong
- This is an extension study, so participants already tolerated the drug; however, long-term side effects are still being monitored, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
Leuven, Belgium
-
Ludug-Maximilians University
München, Germany
-
University College Hospital
London, United Kingdom
-
University Hospital of Madrid
Madrid, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we measure the progression of childhood myotonic dystrophy well enough to test new therapies?
- Scientists hunt for biomarkers to unlock DM1 treatments
- Could virtual reality help kids with a rare muscle disease read emotions better?
- New study tracks Long-Term safety of muscle stiffness drug namuscla
- No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
- Brain scans reveal diabetes link to cognitive decline in rare disease